Affimed N.V.の売上総利益 はN/Aです。
売上総利益は、売上と商品の売上原価との差を収益で除してパーセンテージで表したものです。
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli